# US 2021/0330668 A1 · Treatment of joint conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330668 A1
- Document ID: US20210330668A1
- Status: Published application
- Kind: A1
- Application number: 17/370,538
- Filed: 2021-07-08
- Published: 2021-10-28
- Earliest claimed: 2014-08-18
- Assignees: Ampio Pharmaceuticals, Inc.
- Applicants: Ampio Pharmaceuticals, Inc.
- Inventors: David Bar-Or
- Web page: https://patentgrep.com/patent/US20210330668A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 38/38: Albumins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A method of treating a joint condition comprising administering a composition comprising DA-DKP in a multi-dose regimen.

### Claim 35 (depends on 34)

The method of claim 34, wherein the joint condition is a degenerative joint disease.

### Claim 36 (depends on 35)

The method of claim 35, wherein the degenerative joint disease is osteoarthritis.

### Claim 37 (depends on 34)

The method of claim 34, wherein the joint condition is inflammation.

### Claim 38 (depends on 34)

The method of claim 34, wherein the composition is administered by injection.

### Claim 39 (depends on 34)

The method of claim 34, wherein the concentration of DA-DKP in the composition is selected from about 50 μM to about 350 μM and about 110 μM to about 200 μM.

### Claim 40 (depends on 34)

The method of claim 34, wherein the composition further comprises N-acetyl-tryptophan (NAT), caprylic acid, caprylate or combinations thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the concentration of each of NAT, caprylic acid, caprylate or combinations thereof in the composition is independently selected from about 1 mM to about 20 mM and about 1 mM to about 4 mM.

### Claim 42 (depends on 34)

The method of claim 34, wherein the number of doses in the multi-dose regimen is between 2 and 6 doses per 52 weeks.

### Claim 43 (depends on 34)

The method of claim 34, wherein the amount of each dose is between about 2 mL and about 6 mL.

### Claim 44

A method of treating osteoarthritis in a joint, comprising administering a composition comprising DA-DKP, N-acetyl-tryptophan (NAT) and caprylate in a multi-dose regimen.

### Claim 45 (depends on 44)

The method of claim 44, wherein the composition is administered by injection.

### Claim 46 (depends on 45)

The method of claim 45, wherein the injection is intra-articular.

### Claim 47 (depends on 44)

The method of claim 44, wherein the concentration of DA-DKP in the composition is selected from about 50 μM to about 350 μM and about 110 μM to about 200 μM.

### Claim 48 (depends on 44)

The method of claim 44, wherein the concentration of each of NAT and caprylate is independently selected from about 1 mM to about 20 mM and about 1 mM to about 4 mM.

### Claim 49 (depends on 44)

The method of claim 44, wherein the number of doses in the multi-dose regimen is between 2 and 6 doses per 52 weeks.

### Claim 50 (depends on 44)

The method of claim 44, wherein the amount of each dose is between about 2 mL and about 6 mL.

### Claim 51 (depends on 50)

The method of claim 50, wherein the amount of each dose is about 4 mL.

### Claim 52 (depends on 44)

The method of claim 44, wherein the osteoarthritis is accompanied with pain.

### Claim 53 (depends on 44)

The method of claim 44, wherein the joint is a knee.
